Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Scribe Therapeutics Inc.
Market Cap
$271.05M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.93M
Debt to Equity Ratio
5.26
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$269.87M
Debt to Equity Ratio
1.07
TTM Avg
0.39
3Y Avg
0.60
5Y Avg
7.11
Market Cap
$270.68M
Debt to Equity Ratio
0.02
TTM Avg
0.11
3Y Avg
0.13
5Y Avg
0.16
Market Cap
$270.31M
Debt to Equity Ratio
0.10
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$271.00M
Debt to Equity Ratio
0.49
TTM Avg
0.33
3Y Avg
0.29
5Y Avg
0.26
Market Cap
$272.44M
Debt to Equity Ratio
0.07
TTM Avg
0.07
3Y Avg
0.06
5Y Avg
0.07
Market Cap
$265.42M
Debt to Equity Ratio
0.13
TTM Avg
0.07
3Y Avg
0.16
5Y Avg
0.51
Market Cap
$264.75M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $271.05M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $270.93M | 5.26 | 0.00 | 0.00 | 0.00 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $269.87M | 1.07 | 0.39 | 0.60 | 7.11 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.68M | 0.02 | 0.11 | 0.13 | 0.16 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | 0.10 | 0.03 | 0.03 | 0.03 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | 0.49 | 0.33 | 0.29 | 0.26 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $272.44M | 0.07 | 0.07 | 0.06 | 0.07 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.42M | 0.13 | 0.07 | 0.16 | 0.51 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.75M | 0.00 | 0.00 | 0.02 | 0.02 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.82M | 0.01 | 0.00 | 1.47 | 1.27 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
